| Ticker: NTEG | 2800 Patton Road | |
| Exchange: NASDAQ-National Market | St. Paul, Minnesota 55113 | |
| Industry: Manufacturing | (612) 639-8816 |
| Type of Shares: | Common Shares | Filing Date: | 5/2/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 6/26/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $12.00 - $14.00 | |
| Primary Shares: | 3,000,000 | Offer Price: | $9.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.67 | |
| Offering Amount: | $39,000,000 | Selling: | $0.37 | |
| Expenses: | $400,000 | Reallowance: | $0.10 | |
| Shares Out After: | 9,269,038 |
| Manager | Tier | Phone |
| Piper Jaffray Incorporated | Lead Manager | (612) 342-6000 |
| Montgomery Securities | Co-manager | 4156272220 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $16.55 |
| Net Income: | -$5.05 | -$1.73 | -$0.96 | Liabilities: | $1.73 |
| EPS: | -$0.81 | -$0.22 | Equity: | $14.82 | |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| Integ Incorporated is developing the Lifeguide System, a painless and bloodless hand-held glucose monitoring product for use by people with diabetes. Utilizing the Company's proprietary interstitial fluid Utilizing the Company's proprietary interstitial fluid ("ISF") sampling technology, the Lifeguide System will allow people with diabetes to frequently self-monitor their glucose levels without repeatedly enduring the pain of lancing their fingers to obtain a blood sample. The Company believes that the Lifeguide System represents a significant technological advance in glucose monitoring and will enable people with diabetes to manage their disease more effectively and conveniently. ("ISF") sampling technology, the Lifeguide System will allow people with diabetes to frequently self-monitor their glucose levels without repeatedly enduring the pain of lancing their fingers to obtain a blood sample. The Company believes that the Lifeguide System represents a significant technological advance in glucose monitoring and will enable people with diabetes to manage their disease more effectively and conveniently. |
| Use of Proceeds |
| The proceeds from the offering will be used for continued development and testing of and clinical trials for the Lifeguide System; capital expenditures; research and development, manufacturing and marketing activities; and working capital and other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.